TransCode Therapeutics, Inc.
General ticker "RNAZ" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $367.8M (TTM average)
TransCode Therapeutics, Inc. follows the US Stock Market performance with the rate: 0.9%.
Estimated limits based on current volatility of 2.6%: low 8.43$, high 8.89$
Factors to consider:
- Total employees count: 11 (-42.1%) as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Clinical trial failures, Regulatory and compliance, Market acceptance, Manufacturing risks, Pandemic risks
- Current price 78.6% below estimated low
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [237.40$, 2820.57$]
- 2024-12-30 to 2025-12-30 estimated range: [40.35$, 481.59$]
Financial Metrics affecting the RNAZ estimates:
- Negative: with PPE of -0.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -75.53 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Negative: 0.01 < Interest expense per share per price, % of 0.23
- Negative: 18.93 < Shareholder equity ratio, % of 31.74 <= 41.86
Short-term RNAZ quotes
Long-term RNAZ plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $6.15MM | $18.63MM | $19.42MM |
| Operating Income | $-6.15MM | $-18.63MM | $-19.42MM |
| Non-Operating Income | $-0.69MM | $1.07MM | $0.87MM |
| Interest Expense | $0.10MM | $0.03MM | $0.06MM |
| R&D Expense | $2.75MM | $10.23MM | $12.26MM |
| Income(Loss) | $-6.84MM | $-17.56MM | $-18.55MM |
| Profit(Loss)* | $-6.84MM | $-17.56MM | $-18.55MM |
| Stockholders Equity | $20.40MM | $3.24MM | $1.64MM |
| Assets | $22.94MM | $7.59MM | $5.17MM |
| Operating Cash Flow | $-5.27MM | $-15.76MM | $-18.07MM |
| Capital expenditure | $0.25MM | $0.10MM | $0.04MM |
| Investing Cash Flow | $-0.25MM | $-0.10MM | $-0.04MM |
| Financing Cash Flow | $25.52MM | $0.01MM | $15.91MM |
| Earnings Per Share** | $-649.77 | $-1,082.85 | $-3,419.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.